Results 241 to 250 of about 296,907 (312)

Weight Regain After Incretin Treatment: The Lean Mass Deficit Hypothesis and a Role for Testosterone Combination Therapy in Men

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1RA and triple (GIP)/GLP‐1RA/glucagon agonists achieve placebo‐subtracted weight loss of 15% to 22%. Their long‐term value depends on how well the weight loss is maintained and on the composition of weight loss, not only
Michael Zitzmann   +3 more
wiley   +1 more source

Association Between the GMI/HbA1c Ratio and Microvascular Complications in Type 1 Diabetes: A Multicenter Cross‐Sectional Study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Objective To clarify whether the glucose management indicator (GMI)/glycated haemoglobin (HbA1c) ratio (GMI/HbA1c ratio) is an independent predictor of microvascular complications in Type 1 diabetes (T1D). Design and Methods Multicentre, cross‐sectional, observational study including subjects with T1D with at least 5 years of evolution, users ...
Sandra Herranz‐Antolín   +27 more
wiley   +1 more source

Prevalence of Chronic Complications After Inaugural Admission in Intensive Care Unit for Type 1 Diabetes in the SFDT1 Cohort: The INAUGURAL Study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Inaugural presentation at type 1 diabetes onset, as ketoacidosis, has been associated with poorer glycaemic control, but its relationship to diabetes‐related complications remains unclear. We assessed the association between inaugural intensive care unit (ICU) admission and long‐term diabetes‐related outcomes in adults.
Emmanuel Cosson   +10 more
wiley   +1 more source

Safety, Tolerability, Pharmacokinetics and Exploratory Pharmacodynamics of Melanin‐Concentrating Hormone Receptor‐1 Antagonist RGH‐706 in Healthy and Overweight or Obese Men

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim This Phase 1 program evaluated the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of the novel melanin‐concentrating hormone receptor‐1 antagonist RGH‐706. Methods Study A was a first‐in‐man, randomized trial comprising a double‐blind, placebo‐controlled single‐ascending‐dose part (0.1–162.5 mg) and a two‐way ...
Thomas Brevig   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy